Phaseline

Targets › IL10RB

IL10RB (Interleukin-10 receptor subunit beta): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Dec 2029.

Shared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IFNL1. The IFNLR1/IL10RB dimer is a receptor for the cytokine ligands IFNL2 and IFNL3 and mediates their antiviral activity. (UniProt, Q08334)

Open in Phaseline: the race on IL10RB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Samer GawriehEflepedocokin Alfa (F-652)
IL22 Receptor agonist
IL10RB, IL22RA1Phase 2Alcohol-associated HepatitisDec 2029

Conditions

Alcohol-associated Hepatitis (1)

Modalities

small molecule (1)

Companies

Samer Gawrieh (1)

Related targets

IL22RA1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.